|
Title:
|
Obesity attenuates the effect of sleep apnea on active TGF-ß1 levels and tumor aggressiveness in patients with melanoma
|
|
Author:
|
Cubillos‑Zapata, Carolina; Martínez‑García, Miguel Ángel; Díaz‑García, Elena; Jaureguizar, Ana; Campos‑Rodríguez, Francisco; Sánchez de la Torre, Manuel; Nagore, Eduardo; Martorell‑Calatayud, Antonio; Hernández Blasco, Luis; Pastor, Esther; Abad-Capa, Jorge; Montserrat, Josep Maria; Cabriada‑Nuño, Valentín; Cano‑Pumarega, Irene; Corral-Peñafiel, Jaime; Arias, Eva; Mediano, Olga; Somoza, María; Dalmau-Arias, Joan; Almendros, Isaac; Farré, Ramon; López‑Collazo, Eduardo; Gozal, David; García Río, Francisco
|
|
Notes:
|
Active transforming growth factor-β1 (TGF-β1), a cytokine partially regulated by hypoxia and obesity, has been related with poor prognosis in several tumors. We determine whether obstructive sleep apnea (OSA) increases serum levels of active TGF-β1 in patients with cutaneous melanoma (CM), assess their relationship with melanoma aggressiveness and analyze the factors related to TGF-β1 levels in obese and non-obese OSA patients. In a multicenter observational study, 290 patients with CM were underwent sleep studies. TGF-β1 was increased in moderate-severe OSA patients vs. non-OSA or mild OSA patients with CM. In OSA patients, TGF-β1 levels correlated with mitotic index, Breslow index and melanoma growth rate, and were increased in presence of ulceration or higher Clark levels. In CM patients, OSA was associated with higher TGF-β1 levels and greater melanoma aggressiveness only in non-obese subjects. An in vitro model showed that IH-induced increases of TGF-β1 expression in melanoma cells is attenuated in the presence of high leptin levels. In conclusion, TGF-β1 levels are associated with melanoma aggressiveness in CM patients and increased in moderate-severe OSA. Moreover, in non-obese patients with OSA, TGF-β1 levels correlate with OSA severity and leptin levels, whereas only associate with leptin levels in obese OSA patients.
This study was supported by Grants from Fondo de Investigación Sanitaria (FIS) and Fondos FEDER PI16/00201 and PI19/01612 to F. García-Río, PI19/01363 to C. Cubillos-Zapata and PIE15/00065 to E. López-Collazo. M.A. Martínez-García is supported by the Spanish Ministry of Economy and Competitiveness—Instituto de Salud Carlos III (FIS 2016/ 01772) and co-financed by the European Development Regional Fund. A way to achieve Europe (ERDF). DG is supported in part by National Institutes of Health grants HL130984 and HL140548. The sponsors had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript. |
|
Subject(s):
|
-Cancer
-Diseases
-Medical research
-Oncology
-Pathogenesis |
|
Rights:
|
cc-by (c) Cubillos‑Zapata, Carolina et al., 2020
http://creativecommons.org/licenses/by/4.0/
|
|
Document type:
|
Article
Article - Published version |
|
Published by:
|
Nature Research
|
|
Share:
|
|
